GlassScriptPhysician profile
Myassar Zarif
NPI 1023082914
$438,123.63
in general payments reported to CMS, 2019-2025
58 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139K · 2020: $69K · 2021: $46K · 2022: $102K · 2023: $52K · 2024: $20K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $35K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $6,908 · Travel and Lodging: $6,019 · Consulting Fee: $3,039 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $34,850.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,369.00 |
| Food and Beverage | $6,908.29 |
| Travel and Lodging | $6,019.35 |
| Consulting Fee | $3,039.00 |
| Education | $120.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $141,206.46 | 2019-2025 | Tysabri, Vumerity, Tysabri |
| Horizon Therapeutics Plc | $83,662.89 | 2021-2023 | Uplizna |
| Genzyme Corporation | $34,572.96 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $32,496.20 | 2019-2024 | Ultomiris |
| Emd Serono, INC. | $27,860.09 | 2019-2025 | Mavenclad |
| Amgen INC. | $26,770.94 | 2019-2025 | Uplizna |
| Genentech USA, INC. | $22,229.46 | 2019-2023 | Ocrevus |
| Novartis Pharmaceuticals Corporation | $20,152.68 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $16,116.83 | 2019 | |
| Celgene Corporation | $14,772.27 | 2019-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $11,302.68 | 2020-2023 | Zeposia |
| Tg Therapeutics, INC. | $2,528.23 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $1,003.28 | 2020-2025 | Acthar |
| Greenwich Biosciences, INC. | $257.10 | 2019-2021 | |
| Argenx US, INC. | $256.54 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 56 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myassar Zarif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.